Seres Therapeutics, Inc. (NASDAQ: MCRB) today announced that new preclinical data supporting the development of microbiome therapeutics for immuno-oncology (leveraging ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE